H.C. Wainwright analyst Emily Bodnar has maintained their neutral stance on AGEN stock, giving a Hold rating yesterday.
Emily Bodnar’s rating is based on the promising yet preliminary data from Agenus’s NEOASIS trial, which showed significant pathologic responses in various solid tumors. The trial results indicated a strong efficacy profile, particularly at the 25 mg bot dose, which demonstrated a favorable safety profile and comparable or superior major pathologic response rates compared to the 50 mg dose. However, despite these encouraging findings, Agenus has not yet outlined a comprehensive strategy for advancing its neoadjuvant solid tumor program beyond the current investigational studies.
Given the early stage of development and the absence of a clear commercial pathway, Emily Bodnar has opted for a Hold rating. This reflects a cautious stance as further clinical data and strategic decisions from Agenus are awaited. The Hold rating suggests that while there is potential, the uncertainties surrounding the company’s future plans and the need for more extensive data warrant a wait-and-see approach for investors.